## In the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

- 1. (Currently amended) A product capable of having anti-inflammatory properties, wherein said product is obtainable from starfish, wherein said product is glycoprotein, wherein said glycoprotein has a molecular weight of about 1,100 kDa as measured by 3% polyacrylamide gel electrophoresis, wherein the glycoprotein exhibits at least one characteristic selected from the group consisting of:
  - a) sensitivity to the action of chondroitinase ABC I,
  - b) sensitivity to the action of N-glycanase,
  - c) resistance to the action of chondroitinases ACI and B,
  - d) resistance to the action of proteinase K,
  - e) resistance to the action of papain, and
  - f) sensitivity to the action of neuraminidase.
- 2. (Previously presented) A product according to claim 1 wherein said product is obtainable from the mucus secretions of the starfish.
- 3. (Previously presented) A product according to claim 1 wherein the starfish is *Marthasterias glacialis*.

## Claims 4-6 (Canceled)

7. (Original) A product according to claim 1, said product not having significant anticoagulant properties.

Page 4
Serial No. 10/018,240
Response to Official Action

8.	(Currently amended) A method for the preparation of a product capable of hav-
ing ant	i-inflammatory properties, wherein said product is obtainable from starfish,
wherei	n said product is glycoprotein, wherein said glycoprotein has a molecular weight
of abou	ut 1,100 kDa as measured by 3% polyacrylamide gel electrophoresis, wherein the
glycopr	rotein exhibits at least one characteristic selected from the group consisting of:
	a) sensitivity to the action of chondroitinase ABC I,
	b) sensitivity to the action of N-glycanase,
	c) resistance to the action of chondroitinases ACI and B,
	d) resistance to the action of proteinase K,
	e) resistance to the action of papain, and
•	f) sensitivity to the action of neuraminidase
according to claim 41, said method comprising:	
i i	a) collecting mucus from <i>Marthasterias glaciali</i> s,
	b) removing particulate material by centrifugation,
(	c) subjecting the supernatant to column chromatography,
(	d) eluting the product from the chromatography column of (c), and
(	e) optionally dialysing said eluted product against distilled water.
9.	(Canceled)
10.	(Canceled)
11.	(Original) A pharmaceutical comprising the product of claim 1.
Claims 12-19 (Canceled)	

20. (Previously presented) A composition comprising a glycoprotein obtainable from the mucus secretions of *Marthasterias glacialis* which exhibits a molecular weight of

Page 5 Serial No. 10/018,240 Response to Official Action

about 1,100 kDa as measured by 3 % polyacrylamide gel electrophoresis, and is sensitive to the action of chondroitinase ABC I, sensitive to the action of N-glycanase, sensitive to the action of neuraminidase, resistant to the action of chondroitinases ACI and B, resistant to the action of proteinase K, and resistant to the action of papain.